African Dynamics to Tackle Neglected Diseases

By Monique Wasunna, Head of DNDi Africa

As Head of DNDi Africa, I was honored to bear witness to the special event recently co-hosted in Nairobi by DNDi and the Kenyan Medical Research Institute (KEMRI) to celebrate a decade of Research & Development (R&D) for Neglected Diseases (ND) in Africa. Ten years ago, about 70 participants met in Nairobi to discuss the first steps of what was to lead to 10 years of experiences, learning, and first successes of DNDi in Africa. On June 4th and 5th, we were more than 430 committed and passionate researchers, scientists, decision-makers, and donors to explore the opportunities and remaining challenges for R&D for neglected diseases in Africa. The presence of representatives from 33 countries, of which 21 African countries, and the keen interest of African and international media for the issues we covered is, in itself, an achievement for those who fight to place and keep neglected diseases on national and international public health agendas. 

ASMQ FDC, NECT and Paediatric Benznidazole placed on WHO Essential Medicines Lists

Three treatments developed by DNDi and its partners have been included in the WHO List of Essential Medicines (EML) and the EML for Children (EMLc): The antimalarial fixed-dose combination therapy Artesunate-Mefloquine (ASMQ FDC) in the EML and EMLc, the Nifurtimox-Eflornithine combination therapy (NECT) for the treatment of late-stage sleeping sickness in the EMLc after its inclusion in the EML in 2009, and the paediatric dosage form of benznidazole to treat Chagas disease in the EMLc.
Read the New York Times article

Renewal of MSF support to DNDi

The Médecins Sans Frontières (MSF) International General Assembly in Brussels decided end of June to renew MSF’s political, operational, and financial support to DNDi. MSF will provide EUR 20 million to DNDi over the period 2014 to 2018.

DNDi & Cipla Advance Development of Paediatric 4-in-1 ARVs to Fulfill New WHO Guidelines

The World Health Organization’s new HIV treatment guidelines, released at the 2013 International AIDS Society (IAS) Conference, include new antiretroviral (ARV) therapy (ART) recommendations for HIV-infected children, and will mean that more children will be on better treatments.


Voices for Neglected Diseases

Juscelino Freitas de Oliveira lives in Teresina, Brazil, is infected with visceral leishmaniasis and is also HIV positive. In this moving account, Juscelino speaks about how he got infected with visceral leishmaniasis and his fight against the disease.


Growing Momentum of
A Decade of R&D for Neglected Diseases in Africa : Nairobi Event

On the occasion of DNDi’s 10th anniversary, DNDi and founding partner KEMRI brought together more than 430 key decision-makers and public health actors from Africa and elsewhere for this special event to explore the challenges and opportunities for research & development for neglected diseases in Africa - past and future.

DNDi Selected for Rockefeller Foundation’s ‘Next Century Innovators Award’

DNDi was selected for the Rockefeller Foundation’s ‘Next Century Innovators Awards’, recognizing innovative organizations working to improve conditions for vulnerable populations around the world.

R&D portfolio map now available

DNDi’s R&D Portfolio presenting all DNDi’s current projects from research to implementation is now available online.